Exelixis
EXEL
#1725
Rank
A$15.20 B
Marketcap
$53.24
Share price
-1.16%
Change (1 day)
54.13%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total liabilities

Total liabilities on the balance sheet as of September 2024 : A$1.09 Billion

According to Exelixis's latest financial reports the company's total liabilities are A$1.09 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Exelixis - Total liabilities on balance sheet (from 2001 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31A$0.99 B16.22%
2022-12-31A$0.85 B53.14%
2021-12-31A$0.55 B66.61%
2020-12-31A$0.33 B17.74%
2019-12-31A$0.28 B49.03%
2018-12-31A$0.19 B-59.65%
2017-12-31A$0.47 B-32.48%
2016-12-31A$0.70 B8.17%
2015-12-31A$0.64 B21.33%
2014-12-31A$0.53 B9.25%
2013-12-31A$0.48 B19.9%
2012-12-31A$0.40 B38.45%
2011-12-31A$0.29 B-49.11%
2010-12-31A$0.57 B2.73%
2009-12-31A$0.56 B-13.01%
2008-12-31A$0.64 B73.73%
2007-12-31A$0.37 B-3.38%
2006-12-31A$0.38 B2.72%
2005-12-31A$0.37 B21.03%
2004-12-31A$0.31 B17.76%
2003-12-31A$0.26 B-8.82%
2002-12-31A$0.28 B35.13%
2001-12-31A$0.21 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
A$95.45 B 8,614.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$97.31 B 8,784.15%๐Ÿ‡ซ๐Ÿ‡ท France
A$116.71 B 10,555.07%๐Ÿ‡บ๐Ÿ‡ธ USA
A$122.30 B 11,065.83%๐Ÿ‡บ๐Ÿ‡ธ USA
A$133.31 B 12,071.30%๐Ÿ‡บ๐Ÿ‡ธ USA
A$172.94 B 15,688.55%๐Ÿ‡บ๐Ÿ‡ธ USA
A$202.99 B 18,432.04%๐Ÿ‡บ๐Ÿ‡ธ USA
A$81.9 M-92.52%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.11 B-89.43%๐Ÿ‡บ๐Ÿ‡ธ USA